ConductScience.org, home

Paper20135338

Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.

Han Q and 7 others. Clin Exp Med, 2010. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine. Papers, record 20135338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20135338

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Higher pretherapy and significant decrease during the first 12 months of therapy in serum laminin levels may associate with hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with lamivudine.
PubMed
Journal
Clin Exp Med
PubMed
Year
2010
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.07
iCite
Revised in PubMed
2021-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Han QQunying
2Lou SSai
3Liu ZZhengwen
4Zhang NNi
5Zhang GGuoyu
6Lv YYi
7Duan SShaoqiong
8Li ZZhu

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis B e AntigensMajor topic
Hepatitis B, ChronicMajor topic
LamininMajor topic
LamivudineMajor topic
SerumMajor topic
Adult
Biomarkers
Female
Humans
Male
Prognosis

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16376944The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver.Lab Invest1984https://conductscience.org/library/papers/6376944PubMed
218240869Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.Antivir Ther2007https://conductscience.org/library/papers/18240869PubMed
314697813Viral hepatitis B.Lancet2003https://conductscience.org/library/papers/14697813PubMed
49654535A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.N Engl J Med1998https://conductscience.org/library/papers/9654535PubMed
515740489Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.J Gastroenterol Hepatol2005https://conductscience.org/library/papers/15740489PubMed
615470215Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med2004https://conductscience.org/library/papers/15470215PubMed
72505755Uptake and degradation in vivo and in vitro of laminin and nidogen by rat liver cells.Biochem J1989https://conductscience.org/library/papers/2505755PubMed
810716688Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.Gut2000https://conductscience.org/library/papers/10716688PubMed
92693303Evaluation of serum laminin P1, procollagen-III peptides, and N-acetyl-beta-glucosaminidase for monitoring the activity of liver fibrosis.Hepatogastroenterology1989https://conductscience.org/library/papers/2693303PubMed
109696505Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.J Hepatol1998https://conductscience.org/library/papers/9696505PubMed
118751212The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels.Hepatogastroenterology1995https://conductscience.org/library/papers/8751212PubMed
123802532Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases.Clin Chim Acta1986https://conductscience.org/library/papers/3802532PubMed
139721586Wide distribution of laminin-5 gamma 2 chain in basement membranes of various human tissues.Horm Res1998https://conductscience.org/library/papers/9721586PubMed
141692550Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake.Gastroenterology1990https://conductscience.org/library/papers/1692550PubMed
157635514Tumour necrosis factor-alpha interacts with laminin and functions as a pro-adhesive cytokine.Immunology1995https://conductscience.org/library/papers/7635514PubMed
162707736Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers.Hepatology1989https://conductscience.org/library/papers/2707736PubMed
173894794The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis.Lab Invest1985https://conductscience.org/library/papers/3894794PubMed
189727065Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.J Clin Invest1998https://conductscience.org/library/papers/9727065PubMed
199658370Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.J Viral Hepat1998https://conductscience.org/library/papers/9658370PubMed
2010066373Laminin 5 promotes activation and apoptosis of the T cells expressing alpha3beta1 integrin.Exp Cell Res1999https://conductscience.org/library/papers/10066373PubMed

See all 35 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
30405859A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels.Dis Markers2018https://conductscience.org/library/papers/30405859

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20135338

GET https://conductscience.org/api/papers/v1/20135338/references?page=2